Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY - Dr. Doreen Zhu & Dr. Parminder Judge (Oxford, UK) скачать в хорошем качестве

Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY - Dr. Doreen Zhu & Dr. Parminder Judge (Oxford, UK)

Dr. Doreen Zhu and Dr. Parminder Judge present current and future strategies for renoprotection in patients with chronic kidney disease, and they present the ongoing EASi-KIDNEY trial, which is testing the aldosteron synthese inhibitor vicadrostat (BI 690517) in combination with empagliflozin in patients with chronic kidney disease. Dr. Parminder K Judge is a Senior Clinical Research Fellow based in the Renal Studies Group at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) and an honorary consultant in the Oxford Kidney Unit in the Oxford University Hospitals . Her previous research work includes the UK HARP-III and EMPA-KIDNEY trials. She is the co-principal investigator alongside Will Herrington for the EASi-KIDNEY trial. Dr. Doreen Zhu is an academic clinical lecturer also based in the Renal Studies Group at the CTSU and in the Oxford Kidney Unit. She was a clinical research fellow in the EMPA-KIDNEY trial and is now joint UK representative for the EASi-KIDNEY trial with Parminder Judge. The interview was recorded on December 4th, 2024. Moderators: Prof. Dr. Johannes Mann (Munich, Germany), Prof. Dr. Marcus Säemann (Vieanna, Austria) and Prof. Dr. Gunnar Heine (Frankfurt, Germany). Article discussed: The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Judge PK, Tuttle KR, Staplin N, Hauske SJ, Zhu D, Sardell R, Cronin L, Green JB, Agrawal N, Arimoto R, Mayne KJ, Sammons E, Brueckmann M, Shah SV, Rossing P, Nangaku M, Landray MJ, Wanner C, Baigent C, Haynes R, Herrington WG Nephrol Dial Transplant 2024 doi: 10.1093/ndt/gfae263 Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Vaduganathan M et al. Nat Med doi: 10.1038/s41591-024-03264-4 Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) Green JB et al. Nephrol Dial Transplant. 2023 Mar 31;38(4):894-903. doi: 10.1093/ndt/gfac198 Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C N Engl J Med 2008 doi: 10.1056/NEJMoa0801317 The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Baigent C et al; SHARP Investigators. Lancet 2011 doi: 10.1016/S0140-6736(11)60739-3 Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P; ASi in CKD group Lancet 2024 doi: 10.1016/S0140-6736(23)02408-X. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, de Oliveira Costa J, Falster MO, Pearson SA, Mahaffey KW, Neal B, Agarwal R, Bakris G, Perkovic V, Solomon SD, Vaduganathan M Circulation 2024 doi: 10.1161/CIRCULATIONAHA.123.067584 A Randomized Trial of Intensive versus Standard Blood-Pressure Control. SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. N Engl J Med 2015 doi: 10.1056/NEJMoa1511939 Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. Solomon SD et al.; FINEARTS-HF Committees and Investigators. N Engl J Med 2024 doi: 10.1056/NEJMoa2407107